Colorectal Cancer
Conditions
Brief summary
This is an explorative, phase I clinical trial. The aim of this study is to establish the safety and efficacy of treating patients with early colorectal cancer with calcium electroporation prior to intended curative surgery.
Detailed description
This is an explorative, phase I clinical trial. The aim of this study is to establish the safety and efficacy of treating patients with early colorectal cancer with calcium electroporation as a down staging and immune-response enhancing treatment prior to intended curative surgery. The study involves recruitment of patients with histologically verified rectal and sigmoid colon cancer with no indication for neoadjuvant chemoradiotherapy (experimental or standard care based) prior to intended curative surgery. In total the study will involve 24 patients, of these, 12 patients with rectal cancer and 12 patients with sigmoid colon cancer. In relation to the intervention, clinical examination, blood samples, biopsies and questionnaires will be collected to evaluate safety, tumor respons and immunologic response to the treatment. Patients will be followed for one month after the elective surgery.
Interventions
COMBINATION_PRODUCTCalcium electroporation
Patients with potentially curable colorectal rectal cancer will be treated preoperatively
Sponsors
Zealand University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* • Patients must be mentally capable of understanding the information given. * Patients must give written informed consent. * Histologically verified adenocarcinoma of the rectum or sigmoid colon. * Tumor described as passable at index endoscopy. * Men or women aged at least 18 years. * Case reviewed by MDT (surgery, radiology, oncology). Case considered curable with standard surgical resection. * ASA class I-II (Classification of the American Society of Anesthesiology)
Exclusion criteria
* • Uncorrectable coagulation disorder. * Highly inflamed gastrointestinal tissue which is ulcerated and bleeding * Patients with ICD or pacemaker units. * Ongoing immunosuppressive treatment. * Patients with concomitant use of phenytoin. * Concurrent treatment with an investigational medicinal product. * Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments. * Advanced tumor stages, clinical UICC stage IV. * Indication for neoadjuvant chemoradiation or chemotherapy prior to surgery * Acute surgical resection. * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | 42 days | Safety will be evaluated through registration of adverse events related to the treatment. CTCAE will be used |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histopathological characterization of the tumor | 14 days | ypTNM staging and tumor regression grade according to current standards |
| Immunologic infiltration of the tumor tissue after calcium electroporation | 14 days | Specific immunohistochemical staining for PD-1/PD-L1, CD3 and CD8 will be performed on biopsies and the final surgical specimen. |
| Systemic immune response according to cytokine analysis | 42 days | Blood samples will be collected prior to calcium electroporation and again at follow-up. Multiplex cytokine analysis will be performed |
| Immunoscore classification | 14 days | Tumor infiltration on T-cells and subtypes will be characterized according to the immunoscore classification system. |
| Metastatic ability after potentially curable surgery | 42 days | Cell adhesion assay will be performed on blood samples to evalutate the metastatic ability. |
| Cell proliferation as a marker for metastatic ability | 42 days | Cell proliferation analyses will be performed on blood samples to evaluate metastatic ability |
| Systemic immune response according to flow cytometri | 42 days | Blood samples will be collected prior to calcium electroporation and again at follow-up. Flow cytometri will be performed to evaluate immunological changes to the treatment. |
Countries
Denmark
Contacts
Primary ContactMalene Broholm Andersen, MD
Backup ContactIsmail Gögenur, DMSc
Outcome results
None listed